about
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic studyMatrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel.Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma.Mass spectrometry in the pharmacokinetic studies of anticancer natural products.Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.Nanocarriers in cancer clinical practice: a pharmacokinetic issue.Limits in the use of cPTIO as nitric oxide scavenger and EPR probe in plant cells and seedlings.Light driven water oxidation by a single site cobalt salophen catalyst.Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma.A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study.The development of a matrix-assisted laser desorption/ionization (MALDI)-based analytical method for determination of irinotecan levels in human plasma: preliminary resultsNPQ activation reduces chlorophyll triplet state formation in the moss Physcomitrella patensSimultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical applicationDevelopment and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients
P50
Q28543429-B18174C1-7674-4A29-8E12-64E058742DAEQ35612651-2259BC48-F159-4B41-B339-6F443D775F97Q36033002-C6B1B64F-04A1-4727-A6FD-271EA72B14F7Q36203262-ADD89AA6-A678-4444-B0B5-34D7A71CF3C5Q38568180-232F1FC7-93C1-4DE4-B014-5B7BB08B6110Q38832795-D86C41F6-D1CD-4CA3-9189-665AD33E08C2Q38926510-A5BBBC93-C65C-4E3D-80AD-A8F0112EDAFBQ42575626-2903B20A-29F5-406A-9E69-84CE12AD14CCQ44799057-1E81B196-FAA1-4190-8D11-2F05E18D8E95Q48174042-9817C34A-8FBE-4281-A2E9-BB61585F4105Q52688335-2D861AD8-5FE1-4B05-9878-37A3CD1060C8Q63884143-1994A397-1AFE-4362-B142-A5F7816C738CQ63885995-CE354F03-5600-4535-8D66-34B375C24BF4Q89594587-CB845A38-639A-41BA-8F04-78237C9B0342Q91338838-1F814695-EDC4-462E-B946-690ACB10C1BB
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-3424-8827
@en
name
Bianca Posocco
@ast
Bianca Posocco
@en
Bianca Posocco
@es
Bianca Posocco
@nl
type
label
Bianca Posocco
@ast
Bianca Posocco
@en
Bianca Posocco
@es
Bianca Posocco
@nl
prefLabel
Bianca Posocco
@ast
Bianca Posocco
@en
Bianca Posocco
@es
Bianca Posocco
@nl
P106
P1153
55251736000
P31
P496
0000-0002-3424-8827